Big data on efficacy and toxicity levels for ibrutinib in CLL
The road to individualized treatment for CLL
The impact of the clinical trial of venetoclax (ABT-199) and obinutuzumab in CLL
Can we afford to have CLL patients on a therapy for the rest of their lives?
John Gribben et al.
How can we assess quality of life in AML patients?